University of Texas Southwestern Medical Center
The goal of this clinical trial is to compare the effectiveness of several treatment regimens for stage I triple negative breast cancer before surgery. The main question it aims to answer is if these regimens will reduce or completely remove all cancer cells before surgery.
Inclusion Criteria: * Must have histologically confirmed invasive triple negative breast cancer as defined by ER/PR \<10% and HER2 negative by ASCO/CAP criteria or disease consistent with TNBC by physician assessment, with confirmation by study PI. * Must have untreated, non-metastatic (M0), cT1 (T1a-T1c) N0 disease. Biopsies of suspicious lymph nodes to confirm nodal status are required. * Bilateral or multifocal disease can be included as long as all areas have been biopsied and are consistent with invasive triple negative breast cancer. In the case of bilateral or multifocal disease, the t…
Pembrolizumab 200 mg fixed dose IV once every 3 weeks
Paclitaxel 80 mg/m2 IV once per day on Days 1, 8, 15 of each Cycle
Carboplatin AUC 1.5 IV once per day on Days 1, 8, 15 of each Cycle OR Carboplatin AUC 5 IV once on Day 1 of each Cycle
Arctuva estimate
Verify or correct the compensation shown for this listing.